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Comparative safety of artemether-lumefantrine
and other artemisinin-based combinations in
children: a systematic review
Oluwaseun Egunsola1* and Kazeem A Oshikoya2
Abstract
Background: The purpose of the study was to compare the safety of artemether-lumefantrine (AL) with other
artemisinin-based combinations in children.
Methods: A search of EMBASE (from 1974 to April 2013), MEDLINE (from 1946 to April 2013) and the Cochrane
library of registered controlled trials for randomized controlled trials (RCTs) which compared AL with other
artemisinin-based combinations was done. Only studies involving children ≤ 17 years old in which safety of AL was
an outcome measure were included.
Results: Four thousand, seven hundred and twenty six adverse events (AEs) were recorded in 6,000 patients
receiving AL. Common AEs (≥1/100 and <1/10) included: coryza, vomiting, anaemia, diarrhoea, vomiting and
abdominal pain; while cough was the only very commonly reported AE (≥1/10). AL-treated children have a higher
risk of body weakness (64.9%) than those on artesunate-mefloquine (58.2%) (p = 0.004, RR: 1.12 95% CI: 1.04-1.21).
The risk of vomiting was significantly lower in patients on AL (8.8%) than artesunate-amodiaquine (10.6%) (p = 0.002,
RR: 0.76, 95% CI: 0.63-0.90). Similarly, children on AL had a lower risk of vomiting (1.2%) than chlorproguanil-dapsone-
artesunate (ACD) treated children (5.2%) (p = 0.002, RR: 0.63, 95% CI: 0.47-0.85). The risk of serious adverse events was
significantly lower for AL (1.3%) than ACD (5.2%) (p = 0.002, RR: 0.45, 95% CI: 0.27-0.74).
Conclusion: Artemether-lumefantrine combination is as safe as ASAQ and DP for use in children. Common adverse
events are cough and gastrointestinal symptoms. More studies comparing AL with artesunate-mefloquine and
artesunate-azithromycin are needed to determine the comparative safety of these drugs.
Keywords: Artemether-lumefantrine, Adverse event, Paediatrics, Children, Safety
Background
Malaria, caused by Plasmodium falciparum, is an import-
ant public health problem in Africa. It accounts for an esti-
mated 660,000 deaths in 2010, mostly among African
children [1]. Due to the increasing resistance of malaria
parasite to older anti-malarial drugs, such as chloroquine
and sulphadoxine-pyrimethamine, artemisinin-based com-
bination therapy (ACT) has been recommended by the
World Health Organization (WHO) [2]. This approach
involves the combination of artemisinin, or one of its deriv-
atives, with other anti-malarials, such as amodiaquine,
lumefantrine or sulphadoxine-pyrimethamine. Several stud-
ies have demonstrated the efficacy of ACT for malaria
treatment [3]. A combination therapy explores the syner-
gistic or additive effect of two or more drugs with different
mechanisms of action to improve the therapeutic efficacy,
increase the therapeutic drug life and delay the develop-
ment of resistance to each of the component drugs in the
combination [4].
Artemether-lumefantrine (AL) is one of the most com-
monly used combinations in sub-Saharan Africa. It is
the first-line treatment for uncomplicated malaria in sev-
eral countries. It is available in oral form as a fixed dose
combination (20 mg artemether and 120 mg lumefan-
trine) and given as a six dose regimen for the treatment
of uncomplicated malaria. Artemether has a short half-
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life of 2-3 hours, while lumefantrine has a half-life of
about 5 days [4-6]. Artemether rapidly and extensively
reduces parasite biomass, while lumefantrine clears the
residual parasites from the body [7].
Although AL is widely prescribed, several other com-
binations are increasingly being explored and used but
data are lacking on their safety. Most of the previous
studies have compared the efficacies of AL and other
artemisinin-based combinations, but little or no atten-
tion has been given to their safety. AL has been shown
to be relatively safe when compared with other antima-
larials such as quinine, sulphadoxine-pyrimethamine and
chloroquine [8]. Adverse effects, such as headache, dizzi-
ness, abdominal pain anorexia, anaemia, arthralgia, my-
algia, diarrhoea, vomiting, nausea, weakness and rash,
have been documented [9,10]. Given the wide range of
ACT available for malaria treatment and their potential
adverse effects, it is imperative to compare their safety
profiles. This systematic was, therefore, performed to
compare the safety profiles of AL with other ACT in
children.
Methods
Search strategy
Embase (from January 1974 to April 2013), Medline
(from January 1946 to April 2013) and the Cochrane li-
brary of registered controlled trials for randomized con-
trolled trials (RCTs) were searched for RCTs comparing
AL with other artemisinin-based combinations. Search
terms such as artemisinin or artemether or artesunate or
dihydroartemisinin were combined with lumefantrine or
amodiaquine or sulphadoxine-pyrimethamine or meflo-
quine or chloproguanil or dapsone or piperaquine or
azithromycin. Only studies involving children ≤ 17 years
old in which safety of AL was an outcome measure were
included. There was no restriction on the language of
publication.
Data extraction
Two reviewers extracted data from the included studies
onto data extraction form.
Data extracted from each study included: the com-
parator drug, the number of participants in each arm of
the study, year of the study, duration of follow-up, age of
the participants, dose of drugs administered, the number
of deaths recorded, the number of participants who
withdrew from the study, and the adverse event (AE)
data for both AL and the comparator drugs. All data
were compared and agreed to by both reviewers.
Data quality assessment
To minimize the risk of bias, the quality of included ran-
domized controlled trials was assessed using the
Cochrane collaboration’s tool for assessing risk of bias in
randomized trials [11]; quality of reported safety studies
was also assessed using the modified CONSORT check-
list for reporting of harmful effects [12]. Articles with
modified CONSORT score of ≥6 out of 9 criteria were
considered to have provided good quality safety report-
ing. All RCTs were included for meta-analyses. Highly
biased and poor quality studies were subsequently ex-
cluded in sensitivity analysis. Two reviewers independ-
ently scored and agreed on articles included. Kappa
statistic was used to determine the level of agreements
on the quality assessment between the two reviewers (k
= 0.92) [13].
Data collection and statistical analysis
The relevant data were extracted onto an excel spread
sheet. All studies were grouped based on the comparator
drug and AEs in each pool were aggregated for meta-
analysis. The adverse event profile of AL was used as the
reference against which other artemisinin-based combi-
nations were compared. Meta-analysis was done using
Revman version 5. Relative risk was calculated for all
AEs reported in more than one study. A relative risk
(RR) >1 indicates a higher risk of AE in AL relative to
the comparator. The pooled RR was calculated using the
fixed effect model for homogenous data (I2 ≤50% or
Chi2 p ≥ 0.05) and random effect model for heteroge-
neous data (I2 > 50% or Chi2 p < 0.05) as suggested by
DerSimonian and Laird [14].
Results
Safety information was extracted from 27 RCTs (Figure 1),
which met our inclusion criteria [15-41]. After risk of bias
assessment, 7 studies were of high risk [23-25,34-37]. The
age of the patients ranged between six weeks and 18 years
(Table 1). In all studies, a six-dose regimen of AL (20 mg
artemether and 120 mg lumefantrine) was administered over
three days. The total number of children administered ACT
was 15,119. Four thousand, seven hundred and twenty six
AEs were recorded in 6,000 patients receiving AL. All but
one of the RCTs, were conducted in Africa (Nigeria, Ghana,
Benin, Uganda, Kenya, Tanzania, Ivory Coast, Burkina
Faso, Senegal and Gabon). The only non-African country
was Paupa New Guinea. Common AEs (≥1/100 and
<1/10) among patients receiving AL included: coryza,
vomiting, anaemia, diarrhoea, vomiting and abdominal
pain; while cough was the only very commonly reported
AE (≥1/10) (Table 2). The respiratory and gastrointes-
tinal tracts were the most commonly affected systems
constituting 35% and 33% respectively, of all the re-
ported AEs in AL treated children. Other artemisinin
based combinations compared with AL were: artesunate-
amodiaquine (ASAQ), dihydroartemisinin-piperaquine (DP),
chlorproguanil-dapsone-artesunate (ACD), artesunate-
mefloquine (AM) and artesunate-azithromycin (AAZ).
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AL and DP
Eleven studies involving 5958 children compared AL
with DP [15-25]. There were three cases of death in each
of the drug groups; none was related to the drugs. The
risk of serious adverse events (SAEs) was lower with AL
(0.5%) than DP (1.2%), although this difference was not
statistically significant (p = 0.09, RR 0.62 95%CI 0.36-
1.07). In one of the studies, two unnamed SAEs in AL
arm and four in DP group were considered to have
causal relationship with the drugs [20]. In another study,
one patient receiving AL developed severe anaemia,
which was considered to be possibly associated with the
drug [22]. In Table 3, the children receiving AL had a
minimally higher risk of abdominal pain (10.9%) than
those receiving DP (10.4%) (p = 0.09, RR 1.31, 95% CI
0.99-1.73). After a study with a high risk of bias [24] was
excluded in a sensitivity analysis, the risk of abdominal
pain was statistically significant (p = 0.04). Table 3 shows
that the risks of other common adverse events such as
pruritus, diarrhoea, cough, vomiting and weakness of the
body were not significantly different between the two
drug groups (p > 0.05).
AL and ASAQ
Thirteen studies involving 6018 children comparing AL
with ASAQ were included and analysed [20,26-37]. The
risk of SAEs was not significantly different for both
treatment groups (p = 0.07 RR: 0.54, 95% CI: 0.27-1.05).
The percentage risks of SAEs in the AL and ASAQ
groups were 0.8% and 1.5% respectively. Most of the re-
ported SAEs were judged to be unlikely related to the
medications studied. However in one study [20], four un-
named SAEs in patients receiving ASAQ and two in those
receiving AL were considered to be drug related. There
were only three documented cases of mortality, two in the
AL group and one in the ASAQ group. None of the deaths
was treatment related. Table 3 shows that the risk of
vomiting was significantly lower in patients on AL (8.8%)
than ASAQ (10.6%) (p = 0.002, RR: 0.80, 95% CI: 0.66-
0.97). After excluding one poor quality RCT [34] in a sen-
sitivity analysis, the risk of vomiting remained statistically
significant (p=0.002). The risk of other AEs, such as weak-
ness, pruritus, anaemia, diarrhoea, abdominal pain, an-
orexia and cough, was not statistically significant (p > 0.05)
with or without biased RCTs.
AL and ACD
Three studies comparing AL with ACD involving 3366
children were included in this review [20,26,38]. Two of
these studies compared more than one artemisinin-
based combination. All included RCTs were rated as low
risk. The overall risk of SAE was significantly lower for
AL (1.3%) than ACD (5.2%) (p = 0.002, RR: 0.45, 95% CI:
0.27-0.74). Forty-six (73%) and three (20%) of the SAEs
in the ACD and AL groups, respectively, were due to
oxidative haemolysis. Majority of the haemolytic AEs in
Table 1 Characteristics of treatment groups
Drugs AL and DP AL and ACD AL and ASAQ AL and AM AL and AAZ
Age range(months) 6-168 6-180 1.5-120 6-216 6-59
Median (IQR) duration of follow-up (days) 35(22.8-51.8) 35(12.3-42) 28(21-42) 28 42
Number of studies 11 3 13 2 1
Number of patients in AL arm 3343 1861 3054 239 132
Number in comparator arm 4284 1505 2964 237 129
Figure 1 Flow chart for studies included in the systematic review.
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the ACD group (56.5%) occurred in G6PD deficient chil-
dren. All the three cases of haemolysis in the AL group
were in G6PD normal children. There were three and
four cases of deaths, respectively, for AL and ACD; none
was considered treatment related. In Table 3, the risk of
vomiting was significantly lower for AL (1.2%) than
ACD (5.2%) (p = 0.002, RR: 0.63, 95% CI: 0.47-0.85). No
other adverse event showed a statistically significant dif-
ference between both drugs.
AL and AM
Two studies involving 476 children compared AL with AM
[39,40]. None of the studies reported death or SAEs for
both drugs. In Table 3, pooled analyses of both RCTs
showed a statistically significantly higher risk of weakness
for AL treated children (64.6%) than AM (58.2%) (p = 0.004,
RR: 1.12 95% CI: 1.04-1.21). Vomiting and abdominal pain,
which were the other two AEs reported in both studies,
were not significantly different in both treatment groups.
Table 2 Organ-system classification and risk of adverse events in AL treated children
System organ class Adverse event Number of adverse events Risk (per 1000 patients)
Gastrointestinal disorders Abdominal pain 187 31.2
Anorexia 442 73.7
Diarrhoea 371 61.8
Nausea/vomiting 471 78.5
Others 109 18.2
General disorders Weakness 372 62
Pyrexia 372 62
Mouth ulcer 13 2.2
Salivation 7 1.2
Unable to suck 5 0.8
Body pain 10 1.7
Hypersensitivity reaction 3 0.5
Puffy face 1 0.2
Respiratory disorders Cough 1152 192
Coryza 449 74.8
Dyspnoea 4 0.7
Others 55 9.2
Central Nervous system disorders Headache 228 38
Dizziness 18 3
Insomnia 23 3.8
Convulsion 3 0.5
Nystagmus 1 0.2
Skin and appendages disorders Rash 55 9.2
Pruritus 90 15
Urticaria 2 0.3
Others 35 5.8
Haematological disorders Anaemia 157 26.2
Haemolysis 3 0.5
Thrombocytopaenia 9 1.5
Neutropenia 42 7
Liver and biliary system disorders Jaundice 3 0.5
Elevated ALT 23 3.8
Hepatomegaly 4 0.7
Musculo-skeletal system disorders Joint pain 1 0.2
Cardiovascular disorders Palpitation 6 1
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AL and AAZ
Only one RCT involving 261 patients compared the
safety of AAZ with AL in paediatric patients [41]. This
study showed that children taking AAZ have a signifi-
cantly higher risk of vomiting than those on AL (p =
0.02). The risk of other AEs such as: dizziness, convul-
sion, respiratory and dermatological events were not sig-
nificantly different in both treatment groups.
Discussion
This review identified cough as the most common adverse
event in children receiving AL (Table 2). Other common
adverse events are: abdominal pain, vomiting, anaemia,
headache and diarrhoea. These findings have also been re-
ported by other authors [9,42]. Many of the AEs were ad-
judged to be symptoms of malaria or signs of a progression
of the disease. Generally, AL was well tolerated with only a
few SAEs recorded. Only two unnamed SAEs were consid-
ered to be related to AL treatment. AL treated patients
showed a significantly lower risk of vomiting compared
with ASAQ, ACD and AAZ. A higher risk of weakness was
observed in AL treated children compared with AM.
Due to increased risk of haemolysis, the clinical devel-
opment of ACD, which is a very effective anti-malarial
Table 3 Relative risk of AEs between AL and other artemisinin-based combinations
Relative risk of AEs between AL and DP
Adverse event Risk AL (%) Risk comparator (%) Relative risk (95% CI) P value (*significant) References
Vomiting 10.3 9.7 0.99[0.86-1.13] 0.85 15-24
ǂAnaemia 3.7 10.1 0.45[0.20-1.02] 0.05 18, 20
Abdominal pain 10.9 10.4 1.31[0.99-1.73] 0.06 17, 19, 21, 24
Diarrhoea 13.3 12.6 1.03[0.89-1.20] 0.65 15-18, 20-24
Pruritus 5.8 4.5 1.28[0.81-2.02] 0.30 17, 19, 21, 24
Weakness 16.5 13.3 1.14[0.94-1.39] 0.19 15, 17, 19, 21, 24
Cough 39.8 39.2 0.99[0.92-1.05] 0.65 15, 17-19, 20-22, 24
Anorexia 12.3 11.0 1.07[0.93-1.24] 0.38 15, 17, 19-22
SAE 0.5 1.2 0.62[0.36-1.07] 0.09 15-22
Relative risk of AEs between AL and ASAQ
Abdominal pain 14.5 14.3 0.81[0.46-1.40] 0.45 26, 28, 29, 31-34
Pruritus 8.4 9.5 0.78[0.54-1.11] 0.17 26, 28, 31, 34
Anorexia 14.3 17.6 0.88[0.76-1.03] 0.11 20, 26, 29, 31
ǂAnaemia 8.9 19.1 0.61[0.19-1.90 0.39 20, 30, 31, 33
Headache 13.5 7.9 1.29[0.89-1.87] 0.17 29, 32, 34
Vomiting 8.8 10.6 0.80[0.66-0.97] *0.02 20, 26, 28-31, 33, 34
Weakness 12.8 13.4 0.84[0.63-1.13] 0.25 28, 29, 31, 34
Diarrhoea 12.0 10.4 1.09[0.89-1.32] 0.41 20, 27, 32, 34
Cough 31.4 31.2 1.01[0.91-1.12] 0.84 20, 27, 30, 32, 33
SAE 0.8 1.5 0.54[0.27-1.05] 0.07 20, 30-32
Relative risk of AEs between AL and ACD
ǂAnaemia 2.8 7.2 0.35[0.09-1.43] 0.15 26, 38
Anorexia 11.8 17.8 0.80[0.63-1.00] 0.05 20, 26
Cough 29.2 23.0 1.13[0.96-1.34] 0.15 20, 26
Diarrhoea 6.0 8.6 1.28[0.96-1.73] 0.11 20, 26
Vomiting 1.2 5.2 0.63[0.47-0.85] *0.002 20, 26, 38
SAE 1.3 5.2 0.45[0.27-0.74] *0.002 26, 38
Relative risk of AEs between AL and AM
Weakness 64.9 58.2 1.12[1.04-1.21] *0.004 39, 40
Abdominal pain 1.7 3.8 0.44[0.14-1.41] 0.17 39, 40
Vomiting 21.3 22.8 0.75[0.27-2.05] 0.57 39, 40
ǂ Random effect model.
* (<0.05) statistically significant’.
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drug, was terminated at phase III [43]. A multicentre
RCT by Premji et al. [38] has demonstrated a higher in-
cidence of haemolysis in children receiving ACD than
AL. Given the high prevalence of glucose 6-phosphate
dehydrogenase (G6PD) deficiency (up to 30%) in sub-
Saharan Africa [44], and the fact that G6PD deficient
children are prone to the haemolytic effect of the oxi-
dant metabolite of dapsone [45], halting the develop-
ment of ACD for malaria treatment in Africa was
justified. Malderen et al. [46] showed that G6PD defi-
cient children treated with ACD have a higher, but non-
statistically significant risk of having haemolysis and a
>2 g/dl drop in their haematocrit, than non-deficient pa-
tients. Although ACD development has been stopped, it
may still be relevant in the future fight against malaria.
If such time ever comes, treatment would have to be in-
dividualized, with rapid test of G6PD status done before
ACD prescription. Such tests have been approved by the
US Food and Drug Administration for warfarin therapy
and colon cancer treatment [47,48].
Although mefloquine is associated with neuropsychi-
atric symptoms such as nightmares, hallucinations and
anxiety [49-51], none was recorded in the two RCTs in-
volving AM in this review. The small number of patients
involved in both studies may not be adequately powered
to detect this event. Gastrointestinal events were the
most common adverse events in patients on AM. This is
similar to the report from a study in Nigeria [52]. None
of the gastrointestinal events however showed a signifi-
cant difference between the patients on AM and AL.
Treatment with AL, more than AM, significantly in-
creased the risk of weakness of the body.
Some of the meta-analyses were limited by the relatively
small number of patients in the comparator groups. There-
fore, caution is required when extrapolating the results to
the general population. Besides, such small sample size
may not be sufficiently powered to detect rare events. Sev-
eral of the RCTs reported adverse events rather than ad-
verse reactions of the antimalarial drugs. This made it
impossible to determine the causal relationship between
the antimalarial drugs and the AEs. It was, therefore, diffi-
cult to determine whether an AE is symptomatic of the dis-
ease or drug related. In some other studies, safety
reporting was either selective or inadequate, with some au-
thors failing to indicate the severity of AEs. Some of these
limitations have been identified in studies evaluating the
quality of safety reporting in RCTs [12,53].
Conclusion
Artemether-lumefantrine combination is as safe as
ASAQ and DP for use in children. Common adverse
events are cough and gastrointestinal symptoms. Haem-
olysis in G6PD deficient children makes the use of ACD
undesirable. The few numbers of studies comparing AL
with AM and AAZ would not enable us to make a firm
conclusion on their comparative safety; therefore, more
studies are needed to determine the comparative safety
of AL with AM and AAZ.
Abbreviations
AAZ: Artesunate-azithromycin; ACD: Chorproguanil-dapsone-artesunate;
ACT: Artemisinin combination therapy; AE: Adverse event; AL: Artemether-
lumefantrine; AM: Artesunate-mefloquine; ASAQ: Artesunate-amodiaquine;
CI: Confidence interval; CONSORT: CONsolidated Standards of Reporting
Trials; DP: Dihydroartemisinine-piperaquine; G6PD: Glucose-6-phosphate
dehydrogenase; RCT: Randomized controlled trial; RR: Relative risk;
SAE: Serious adverse event; WHO: World Health Organization.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
OE and KAO conceived the idea and planned the research; OE performed
the database search; OE and KAO reviewed the retrieved papers for eligibility
and performed the data extraction; OE and KAO performed the risk of bias
assessment; OE performed the meta-analyses; OE wrote the first draft; KO
edited and reviewed the manuscript; OE prepared the final draft. Both OE
and KAO agreed to the final draft of the manuscript.
Author details
1Academic Division of Child Health, University of Nottingham, Derbyshire
Children’s Hospital, Derby DE22 3DT, UK. 2Department of Pharmacology,
Lagos State University College of Medicine, IkejaLagos state, Nigeria.
Received: 10 July 2013 Accepted: 28 October 2013
Published: 1 November 2013
References
1. World Health Organization: Malaria. http://www.who.int/mediacentre/
factsheets/fs094/en/.
2. WHO: Antimalarial drug combination therapy: report of a technical
consultation. Geneva: World Health Organization; 2001. http://whqlibdoc.
who.int/hq/2001/WHO_CDS_RBM_2001.35.pdf.
3. Makanga M, Krudsood S: The clinical efficacy of artemether/lumefantrine
(Coartem). Malar J 2009, 8(Suppl 1):S5.
4. Kokwaro G, Mwai L, Nzila A: Artemether/lumefantrine in the treatment of
uncomplicated falciparum malaria. Expert Opin Pharmacother 2007,
8:75–94.
5. Ezzet F, Mull R, Karbwang J: Population pharmacokinetics and therapeutic
response of CGP 56697(artemether + benflumetol) in malaria patients.
Br J Clin Pharmacol 1998, 46:553–561.
6. Lefevre G, Thomsen MS: Clinical pharmacokinetics of artemether and
lumefantrine (Riamet®). Clin Drug Investig 1999, 18:467–480.
7. Premji ZG: Coartem®: the journey to the clinic. Malar J 2009, 8:S3.
8. Falade C, Manyando C: Safety profile of Coartem: the evidence base.
Malar J 2009, 8:S6.
9. Artemether-lumefantrine full prescribing information. [http://www.
pharma.us.novartis.com/cs/www.pharma.us.novartis.com/product/pi/pdf/
coartem.pdf]
10. Bakshi R, Hermeling-Fritz I, Gathmann I, Alteri E: An integrated assessment
of the clinical safety of artemether-lumefantrine: a new oral fixed-dose
combination antimalarial drug. Trans R Soc Trop Med Hyg 2000,
94:419–424.
11. Cochrane bias method group: Assessing risk of bias in included studies.
http://bmg.cochrane.org/assessing-risk-bias-included-studies.
12. de Vries TW, van Roon EN: Low quality of reporting adverse drug
reactions in paediatric randomised controlled trials. Arch Dis Child 2010,
95:1023–1026.
13. Viera AJ, Garrett JM: Understanding interobserver agreement: the kappa
statistic. Fam Med 2005, 37:360–363.
14. DerSimonian R, Laird N: Meta-analysis in clinical trials. Contr Clin Trials
1986, 7:177–188.
15. Arinaitwe E, Sandison TG, Wanzira H, Kakuru A, Homsy J, Kalamya J, Kamya
MR, Vora N, Greenhouse B, Rosenthal PJ, Tappero J, Dorsey G: Artemether-
Egunsola and Oshikoya Malaria Journal 2013, 12:385 Page 6 of 8
http://www.malariajournal.com/content/12/1/385
lumefantrine versus dihydroartemisinin-piperaquine for falciparum mal-
aria: a longitudinal, randomized trial in young Ugandan children.
Clin Infect Dis 2009, 49:1629–1637.
16. Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Menéndez C, Nambozi
M, Valéa I, Nabasumba C, Sasi P, Bacchieri A, Corsi M, Ubben D, Talisuna A,
D’Alessandro U: Dihydroartemisinin-piperaquine and artemether-
lumefantrine for treating uncomplicated malaria in African children: a
randomised, non-inferiority trial. PLoS One 2009, 4:e7871.
17. Kamya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, Staedke SG,
Talisuna AO, Greenhouse B, Nosten F, Rosenthal PJ, Wabwire-Mangen F,
Dorsey G: Artemether-lumefantrine versus dihydroartemisinin-
piperaquine for treatment of malaria: a randomized trial. PLoS Clin Trials
2007, 2:e20.
18. Katrak S, Gasasira A, Arinaitwe E, Kakuru A, Wanzira H, Bigira V, Sandison TG,
Homsy J, Tappero JW, Kamya MR, Dorsey G: Safety and tolerability of
artemether-lumefantrine versus dihydroartemisinin-piperaquine for mal-
aria in young HIV-infected and uninfected children. Malar J 2009, 8:272.
19. Yeka A, Dorsey G, Kamya MR, Talisuna A, Lugemwa M, Rwakimari JB,
Staedke SG, Rosenthal PJ, Wabwire-Mangen F, Bukirwa H: Artemether-lume-
fantrine versus dihydroartemisinin-piperaquine for treating uncompli-
cated malaria: a randomized trial to guide policy in Uganda. PLoS One
2008, 3:e2390.
20. Four Artemisinin-Based Combinations (4ABC) Study Group: A head-to-head
comparison of four artemisinin-based combinations for treating uncom-
plicated malaria in African children: a randomized trial. PLoS Med 2011,
8:e1001119.
21. Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Séré Y, Rosenthal PJ,
Ouédraogo JB: Randomized comparison of amodiaquine plus
sulfadoxine-pyrimethamine, artemether-lumefantrine, and
dihydroartemisinin-piperaquine for the treatment of uncomplicated
Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis 2007,
45:1453–1461.
22. Nambozi M, Van Geertruyden JP, Hachizovu S, Chaponda M, Mukwamataba
D, Mulenga M, Ubben D, D’Alessandro U: Safety and efficacy of
dihydroartemisinin-piperaquine versus artemether-lumefantrine in the
treatment of uncomplicated Plasmodium falciparum malaria in Zambian
children. Malar J 2011, 10:50.
23. Creek D, Bigira V, Arinaitwe E, Wanzira H, Kakuru A, Tappero J, Kamya MR,
Dorsey G, Sandison TG: Increased risk of early vomiting among infants
and young children treated with dihydroartemisinin-piperaquine com-
pared with artemether-lumefantrine for uncomplicated malaria.
Am J Trop Med Hyg 2010, 83:873–875.
24. Mens PF, Sawa P, van Amsterdam SM, Versteeg I, Omar SA, Schallig HD,
Kager PA: A randomized trial to monitor the efficacy and effectiveness
by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-
piperaquine for treatment and transmission control of uncomplicated
Plasmodium falciparum malaria in western Kenya. Malar J 2008, 7:237.
25. Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, Gomorrai PS, Oa O, Griffin
S, Kotab K, Suano P, Tarongka N, Ura A, Lautu D, Page-Sharp M, Wong R,
Salman S, Siba P, Ilett KF, Davis TM: A trial of combination antimalarial
therapies in children from Papua New Guinea. N Engl J Med 2008,
359:2545–2557.
26. Owusu-Agyei S, Asante KP, Owusu R, Adjuik M, Amenga-Etego S, Dosoo DK,
Gyapong J, Greenwood B, Chandramohan D: An open label, randomised
trial of artesunate + amodiaquine, artesunate + chlorproguanil-dapsone
and artemether-lumefantrine for the treatment of uncomplicated mal-
aria. PLoS One 2008, 3:e2530.
27. Adjei GO, Kurtzhals JA, Rodrigues OP, Alifrangis M, Hoegberg LC, Kitcher ED,
Badoe EV, Lamptey R, Goka BQ: Amodiaquine-artesunate vs artemether-
lumefantrine for uncomplicated malaria in Ghanaian children: a randomized
efficacy and safety trial with one year follow-up. Malar J 2008, 7:127.
28. Michael OS, Gbotosho GO, Folarin OA, Okuboyejo T, Sowunmi A, Oduola
AM, Happi CT: Early variations in Plasmodium falciparum dynamics in
Nigerian children after treatment with two artemisinin-based combinations:
implications on delayed parasite clearance. Malar J 2010, 9:335.
29. Faucher JF, Aubouy A, Adeothy A, Cottrell G, Doritchamou J, Gourmel B,
Houzé P, Kossou H, Amedome H, Massougbodji A, Cot M, Deloron P:
Comparison of sulfadoxine-pyrimethamine, unsupervised artemether-
lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose
formulation for uncomplicated Plasmodium falciparum malaria in Benin: a
randomized effectiveness noninferiority trial. J Infect Dis 2009, 200:57–65.
30. Kobbe R, Klein P, Adjei S, Amemasor S, Thompson WN, Heidemann H,
Nielsen MV, Vohwinkel J, Hogan B, Kreuels B, Bührlen M, Loag W, Ansong D,
May J: A randomized trial on effectiveness of artemether-lumefantrine
versus artesunate plus amodiaquine for unsupervised treatment of
uncomplicated Plasmodium falciparum malaria in Ghanaian children.
Malar J 2008, 7:261.
31. Maiteki-Sebuguzi C, Jagannathan P, Yau VM, Clark TD, Njama-Meya D, Nzarubara
B, Talisuna AO, Kamya MR, Rosenthal PJ, Dorsey G, Staedke SG: Safety and
tolerability of combination antimalarial therapies for uncomplicated falcip-
arum malaria in Ugandan children. Malar J 2008, 7:106.
32. Bukirwa H, Yeka A, Kamya MR, Talisuna A, Banek K, Bakyaita N, Rwakimari JB,
Rosenthal PJ, Wabwire-Mangen F, Dorsey G, Staedke SG: Artemisinin
combination therapies for treatment of uncomplicated malaria in
Uganda. PLoS Clin Trials 2006, 1:e7.
33. Falade CO, Ogundele AO, Yusuf BO, Ademowo OG, Ladipo SM: High efficacy
of two artemisinin-based combinations (artemether-lumefantrine and
artesunate plus amodiaquine) for acute uncomplicated malaria in Ibadan,
Nigeria. Trop Med Int Health 2008, 13:635–643.
34. Gbotosho GO, Sowunmi A, Okuboyejo TM, Happi CT, Folarin OA, Michael
OS, Adewoye EO: Therapeutic efficacy and effects of artemether-
lumefantrine and artesunate-amodiaquine coformulated or copackaged
on malaria-associated anemia in children with uncomplicated
Plasmodium falciparum malaria in Southwest Nigeria. Am J Trop Med Hyg
2011, 84:813–819.
35. Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C,
Greenwood BM, Whitty CJ: Amodiaquine alone, amodiaquine +
sulfadoxine-pyrimethamine, amodiaquine + artesunate, and artemether-
lumefantrine for outpatient treatment of malaria in Tanzanian children: a
four-arm randomised effectiveness trial. Lancet 2005, 365:1474–1480.
36. Mårtensson A, Strömberg J, Sisowath C, Msellem MI, Gil JP, Montgomery
SM, Olliaro P, Ali AS, Björkman A: Efficacy of artesunate plus amodiaquine
versus that of artemether-lumefantrine for the treatment of uncomplicated
childhood Plasmodium falciparum malaria in Zanzibar, Tanzania.
Clin Infect Dis 2005, 41:1079–1106.
37. Meremikwu M, Alaribe A, Ejemot R, Oyo-Ita A, Ekenjoku J, Nwachukwu C,
Ordu D, Ezedinachi E: Artemether-lumefantrine versus artesunate plus
amodiaquine for treating uncomplicated childhood malaria in Nigeria:
randomized controlled trial. Malar J 2006, 5:43.
38. Premji Z, Umeh RE, Owusu-Agyei S, Esamai F, Ezedinachi EU, Oguche S,
Borrmann S, Sowunmi A, Duparc S, Kirby PL, Pamba A, Kellam L, Guiguemdé
R, Greenwood B, Ward SA, Winstanley PA: Chlorproguanil-dapsone-artesu-
nate versus artemether-lumefantrine: a randomized, double-blind phase
III trial in African children and adolescents with uncomplicated
Plasmodium falciparum malaria. PLoS One 2009, 4:e6682.
39. Toure OA, Kouame MG, Didier YJ, Berenger AA, Djerea K, Genevieve GO,
Penali LK: Artesunate/mefloquine paediatric formulation vs. artemether/
lumefantrine for the treatment of uncomplicated Plasmodium falciparum
in Anonkoua kouté, Côte d’Ivoire. Trop Med Int Health 2011, 16:290–297.
40. Faye B, Ndiaye JL, Tine R, Sylla K, Gueye A, Lô AC, Gaye O: A randomized
trial of artesunate mefloquine versus artemether lumefantrine for the
treatment of uncomplicated Plasmodium falciparum malaria in
Senegalese children. Am J Trop Med Hyg 2010, 82:140–144.
41. Sykes A, Hendriksen I, Mtove G, Mandea V, Mrema H, Rutta B, Mapunda E,
Manjurano A, Amos B, Reyburn H, Whitty CJ: Azithromycin plus artesunate
versus artemether-lumefantrine for treatment of uncomplicated malaria
in Tanzanian children: a randomized, controlled trial. Clin Infect Dis 2009,
49:1195–1201.
42. Makanga M, Premji Z, Falade C, Karbwang J, Mueller EA, Andriano K, Hunt P,
De Palacios PI: Efficacy and safety of the six-dose regimen of artemether-
lumefantrine in pediatrics with uncomplicated Plasmodium falciparum
malaria: a pooled analysis of individual patient data. Am J Trop Med Hyg
2006, 74:991–998.
43. Update on GSK’s malaria treatments: Dacart and Lapdap. http://www.gsk.
com/media/press-releases/2008/update-on-gsks-malaria-treatments-dacart-
and-lapdap.html.
44. Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, Hogg MM,
Battle KE, Padilla CD, Baird JK, Hay SI: G6PD deficiency prevalence and
estimates of affected populations in malaria endemic countries: a
geostatistical model-based map. PLoS Med 2012, 9:e1001339.
45. Carrazza MZ, Carrazza FR, Oga S: Clinical and laboratory parameters in
dapsone acute intoxication. Rev Saude Publica 2000, 34:396–401.
Egunsola and Oshikoya Malaria Journal 2013, 12:385 Page 7 of 8
http://www.malariajournal.com/content/12/1/385
46. Van Malderen C, Van Geertruyden JP, Machevo S, González R, Bassat Q,
Talisuna A, Yeka A, Nabasumba C, Piola P, Daniel A, Turyakira E, Forret P, Van
Overmeir C, van Loen H, Robert A, D’ Alessandro U: Glucose-6-phosphate
dehydrogenase deficiency, chlorproguanil-dapsone with artesunate and
post-treatment haemolysis in African children treated for uncomplicated
malaria. Malar J 2012, 11:139.
47. FDA clears genetic lab test for warfarin Sensitivity. www.fda.gov/newsevents/
newsroom/pressannouncements/2007/ucm108984.htm.
48. FDA approves Erbitux for colorectal cancer. http://www.fda.gov/NewsEvents/
Newsroom/PressAnnouncements/2004/ucm108244.htm.
49. Mayxay M, Khanthavong M, Lindegårdh N, Keola S, Barends M, Pongvongsa
T, Yapom R, Annerberg A, Phompida S, Phetsouvanh R, White NJ, Newton
PN: Randomized comparison of chloroquine plus sulfadoxine-
pyrimethamine versus artesunate plus mefloquine versus artemether-
lumefantrine in the treatment of uncomplicated falciparum malaria in
the Lao People’s Democratic Republic. Clin Infect Dis 2004, 39:1139–1147.
50. Schlagenhauf P, Adamcova M, Regep L, Schaerer MT, Bansod S, Rhein HG:
Use of mefloquine in children - a review of dosage, pharmacokinetics
and tolerability data. Malar J 2011, 10:292.
51. Lariam (mefloquine hydrochloride) 250 mg tablets: Detailed View: Safety
Labeling Changes Approved By FDA Center for Drug Evaluation and Research
(CDER). 2009. http://www.fda.gov/Safety/MedWatch/SafetyInformation/
ucm181182.htm.
52. Agomo PU, Meremikwu MM, Watila IM, Omalu IJ, Odey FA, Oguche S,
Ezeiru VI, Aina OO: Efficacy, safety and tolerability of artesunate-
mefloquine in the treatment of uncomplicated Plasmodium falciparum
malaria in four geographic zones of Nigeria. Malar J 2008, 7:172.
53. Anderson M, Choonara I: A systematic review of safety monitoring and
drug toxicity in published randomized controlled trials of antiepileptic
drugs in children over a 10-year period. Arch Dis Child 2011, 95:731–738.
doi:10.1186/1475-2875-12-385
Cite this article as: Egunsola and Oshikoya: Comparative safety of
artemether-lumefantrine and other artemisinin-based combinations in
children: a systematic review. Malaria Journal 2013 12:385.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Egunsola and Oshikoya Malaria Journal 2013, 12:385 Page 8 of 8
http://www.malariajournal.com/content/12/1/385
